Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft™
16 avr. 2024 07h00 HE
|
Marizyme Inc.
JUPITER, FL, April 16, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Marizyme, Inc. ("Marizyme", OTCQB: MRZM) announces today a Co-Development Agreement (the “Agreement”) with Qualigen Therapeutics,...
Marizyme CEO Delivers Business Update
23 oct. 2023 09h00 HE
|
Marizyme Inc.
JUPITER, FL, Oct. 23, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - Marizyme, Inc. ("Marizyme" or the "Company") (OTCQB: MRZM), today provided the following business update to the stockholders and the...
Marizyme, Inc. Announces FDA Clearance for Flagship Product, DuraGraft™
06 oct. 2023 09h00 HE
|
Marizyme Inc.
DuraGraft is the first and only FDA cleared medical device for use as an intra-operative vascular conduit storage and flushing solution used during CABG surgeries JUPITER, FL, Oct. 06, 2023 (GLOBE...
Marizyme Announces IP Developments for DuraGraft® and Its Pipeline Products
10 mai 2023 08h00 HE
|
Marizyme Inc.
JUPITER, FL, May 10, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Marizyme, Inc. ("Marizyme" or the "Company") (OTCQB: MRZM), a multi-technology biomedical company focused on the accelerated...
Marizyme CEO Delivers Business Update
03 mai 2023 08h00 HE
|
Marizyme Inc.
JUPITER, FL, May 03, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Marizyme, Inc. ("Marizyme" or the "Company") (OTCQB: MRZM), today provided the following business update to the stockholders and the...
Marizyme Announces Allowance of Patent Application for Flagship Product DuraGraft by United States Patent and Trademark Office
05 janv. 2022 08h30 HE
|
Marizyme Inc.
Jupiter, FL, Jan. 05, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Marizyme, Inc. (“Marizyme” or the “Company”) (OTCQB: MRZM) is pleased to announce that the United States Patent and Trademark...
Marizyme Announces the Closing of My Health Logic Acquisition Along With Initial Financing
23 déc. 2021 15h24 HE
|
Marizyme Inc.
JUPITER, Fla., Dec. 23, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Marizyme Inc. (“Marizyme” or the “Company”) (OTCQB:MRZM), is pleased to announce the closing of its acquisition of My Health...
Marizyme Inc. Announces Results of GOAL Study Presented at 7th Annual International Coronary Congress
03 déc. 2021 16h30 HE
|
Marizyme Inc.
JUPITER, FL, Dec. 03, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Marizyme Inc. (MRZM), a biotechnology company engaged in the development and commercialization of products to prevent, treat and...
Marizyme Announces Expansion of Patent Portfolio Into Several Key Territories
03 déc. 2021 10h37 HE
|
Marizyme Inc.
Jupiter, FL, Dec. 03, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Marizyme Inc. (MRZM), a biotechnology company engaged in the development and commercialization of advanced healthcare products to...
Marizyme is Pleased to Announce the Appointment of David Barthel as CEO
16 nov. 2021 14h55 HE
|
Marizyme Inc.
JUPITER, Fla., Nov. 16, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Marizyme Inc. (“Marizyme” or the “Company”) (OTCQB:MRZM), is pleased to announce the hiring of Mr. David Barthel as the Chief...